64 Matching Annotations
  1. Jul 2025
  2. May 2025
  3. Apr 2025
  4. Feb 2025
  5. Dec 2024
  6. Nov 2024
  7. Oct 2024
  8. Jul 2024
  9. May 2024
  10. Apr 2024
  11. Mar 2024
  12. Jan 2024
  13. Dec 2023
  14. Nov 2023
  15. Oct 2023
  16. Sep 2023
  17. Aug 2023
  18. May 2023
  19. Mar 2023
  20. Jan 2023
  21. Dec 2022
  22. Nov 2022
  23. Jun 2022
  24. Apr 2022
  25. Mar 2022
  26. Feb 2022
  27. Dec 2021
  28. Sep 2021
  29. Aug 2021
  30. Jul 2021
  31. Jun 2021
  32. Apr 2021
  33. Feb 2021
  34. Jan 2021
  35. Sep 2020
  36. May 2020
    1. The immunohistochemical specificity of anti-IL-1β (catalogue no. 12242; Cell Signaling Technology) has been validated by the manufacturer. Thus, by immunohistochemistry, it successfully detects IL-1β immunoreactive cells in human colonic sections from individuals with chronic colitis. Further, by western blotting, the same antibody detects mature recombinant human and mouse IL-1β and the human precursor (molecular mass of 34 kDa) in extracts of Raw 264.7 and human monocyte-derived THP-1 cells, following exposure to Brefeldin and lipopolysaccharide (LPS), respectively. Anti-IL-1β was replaced with diluent to act as negative controls. As further controls, paraffin sections of THP-1 cells, harvested after incubation with LPS (100 ng/ml for 3 h) and without (from Cell Signaling Technology), were evaluated in this laboratory for IL-1β immunohistochemical specificity. The immunostaining protocol for IL-1β was tested with formalin-fixed tonsil sections, supplied by Department of Surgery, University of Auckland. Sections from selected pancreas and tonsil were immunostained for IL-1β in two separate sections. They were then exposed to rabbit anti-CD68 or rabbit anti-CD3, followed by donkey anti-rabbit IgG-biotin and then streptavidin–Alexa 568. Pancreatic sections were immunostained subsequently for insulin as above, followed by donkey anti-guinea pig IgG–Alexa 488.

      IHC for IL-1b

  37. Jan 2020
  38. Nov 2018
  39. Nov 2017